Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sana Biotechnology, Inc. regarding a class action lawsuit due to alleged misleading statements and financial misrepresentations during a specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from March 17, 2023, to November 4, 2024 [3]. - Allegations include that Sana was at significant risk of insufficient funds to maintain operations and advance product candidates, specifically SC291 in oncology, SC379, and SG299, which were less promising than represented [3]. - It is claimed that to preserve cash, Sana was likely to decrease funding for these product candidates and significantly reduce its workforce, leading to overstated financial capacity [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by May 20, 2025, to participate in potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [5]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sana Biotechnology, Inc. regarding a class action lawsuit due to allegations of misleading statements and financial misrepresentation during a specified class period [1][2]. Group 1: Allegations - The complaint alleges that during the class period from March 17, 2023, to November 4, 2024, Sana Biotechnology was at significant risk of having insufficient funds to maintain its operations and advance its product candidates [1]. - It is claimed that product candidates SC291 in oncology, SC379, and SG299 were less promising than what the defendants had communicated to investors [1]. - The company is likely to decrease funding for or discontinue certain product candidates and significantly reduce its workforce to preserve cash for more promising projects [1]. - The defendants allegedly overstated Sana's financial capacity to maintain operations and advance existing product candidates, leading to materially false and misleading public statements [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of SANA during the specified timeframe are encouraged to register for the class action, with a deadline of May 20, 2025, to seek lead plaintiff status [2]. - Registered shareholders will be enrolled in a portfolio monitoring software to receive updates throughout the lifecycle of the case [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors who have suffered due to deceit, fraud, and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements or omissions that led to artificial inflation of stock prices [3].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39941 Sana Biotechnology, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 83-1381173 (State or other jurisdi ...

Exhibit 1.1 SANA BIOTECHNOLOGY, INC. COMMON STOCK SALES AGREEMENT May 8, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, NY 10017 Ladies and Gentlemen: Sana Biotechnology, Inc., a Delaware corporation (the "Company"), confirms its agreement (this "Agreement") with TD Securities (USA) LLC ("TD Cowen"), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time during the term of this Agreement, on the terms and subject to the conditions set forth herein, it may issue an ...

Core Insights - Sana Biotechnology, Inc. has made significant progress in developing therapies for type 1 diabetes, with promising clinical results indicating that hypoimmune-modified pancreatic islet cells can function without immunosuppression and maintain stable C-peptide production post-transplant [1][2][5] - The company is advancing its pipeline with ongoing trials for SC291 and SC262 targeting B-cell mediated autoimmune diseases and relapsed/refractory B-cell malignancies, respectively, with data expected in 2025 [1][7] - Financially, Sana reported a cash position of $104.7 million as of Q1 2025, with a cash runway expected to extend into 2026 [1][6] Clinical Developments - The ongoing UP421 trial has shown that hypoimmune-modified pancreatic islets can evade immune detection and continue to function three months post-transplant, which is a critical step towards a functional cure for type 1 diabetes [2][5] - Preclinical data for SC451 demonstrated 15-month durability of glycemic control in a mouse model, with no histological abnormalities, supporting its potential for future clinical application [4] - The GLEAM and VIVID trials are currently enrolling patients, with expectations to report clinical data in 2025 [1][7] Financial Performance - For Q1 2025, the company reported a net loss of $49.4 million, or $0.21 per share, a significant reduction from a net loss of $107.5 million, or $0.49 per share, in Q1 2024 [6][14] - Research and development expenses decreased to $37.2 million in Q1 2025 from $56.4 million in the same period in 2024, primarily due to lower personnel-related and clinical development costs [6][14] - The company’s non-GAAP operating cash burn for Q1 2025 was $46.6 million, down from $58.7 million in Q1 2024, indicating improved cash management [10][19]

Core Viewpoint - A class action securities lawsuit has been filed against Sana Biotechnology, Inc. due to alleged securities fraud affecting investors between March 17, 2023, and November 4, 2024 [1][2]. Group 1: Allegations of Fraud - The lawsuit claims that Sana Biotechnology was at significant risk of having insufficient funds to maintain its operations and advance its product candidates [2]. - It is alleged that the product candidates SC291 in oncology, SC379, and SG299 were less promising than what the defendants had communicated to investors [2]. - The company is likely to decrease funding for or discontinue certain product candidates and significantly reduce its workforce to preserve cash for more promising projects [2]. - Defendants are accused of overstating Sana's financial capacity to maintain operations and advance existing product candidates, leading to materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until May 20, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sana Biotechnology, Inc. regarding a class action lawsuit due to allegations of misleading statements and financial misrepresentation during a specified class period [1][3]. Summary by Relevant Sections Class Period and Allegations - The class period for the lawsuit is from March 17, 2023, to November 4, 2024 [3]. - Allegations include that Sana was at significant risk of insufficient funds to maintain operations and advance product candidates [3]. - Specific product candidates, SC291 in oncology, SC379, and SG299, were claimed to be less promising than represented [3]. - The company was likely to decrease funding for these candidates and reduce headcount to preserve cash for more promising products [3]. - Public statements made by the defendants were alleged to be materially false and misleading throughout the relevant period [3]. Next Steps for Shareholders - Shareholders are encouraged to register for the class action by May 20, 2025, to participate in potential recovery [4]. - Registration will include enrollment in a portfolio monitoring software for status updates on the case [4]. Law Firm's Commitment - The Gross Law Firm aims to protect investors' rights against deceit and fraud, ensuring companies adhere to responsible business practices [5].

Core Viewpoint - A class action securities lawsuit has been filed against Sana Biotechnology, Inc. due to alleged securities fraud affecting investors between March 17, 2023, and November 4, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Sana Biotechnology, Inc. misrepresented its financial stability and the potential of its product candidates, specifically SC291 in oncology, SC379, and SG299 [2]. - Allegations include that Sana was at significant risk of insufficient funds to maintain operations and advance product candidates, and that the company was likely to decrease funding for certain projects and reduce its workforce [2]. Group 2: Investor Information - Investors who suffered losses during the specified timeframe have until May 20, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Core Viewpoint - A class action securities lawsuit has been filed against Sana Biotechnology, Inc. alleging securities fraud that affected investors between March 17, 2023, and November 4, 2024 [1][2] Group 1: Allegations of Fraud - The lawsuit claims that Sana was at significant risk of having insufficient funds to maintain its operations and advance its product candidates [2] - It is alleged that product candidates SC291 in oncology, SC379, and SG299 were less promising than previously communicated to investors [2] - The company is likely to decrease funding for or discontinue certain product candidates and significantly reduce its headcount to preserve cash for more promising projects [2] - Defendants are accused of overstating Sana's financial capacity to maintain operations and advance existing product candidates [2] - Public statements made by the defendants were materially false and/or misleading throughout the relevant period [2] Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until May 20, 2025, to request to be appointed as lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees [3] Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the U.S. [4]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sana Biotechnology, Inc. regarding a class action lawsuit due to allegations of misleading statements and financial misrepresentation during a specified class period [1][2]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from March 17, 2023, to November 4, 2024, Sana Biotechnology made materially false and misleading statements, failing to disclose significant risks regarding its financial stability and product candidates [1]. - Specific allegations include: - Sana was at significant risk of having insufficient funds to maintain operations and advance product candidates [1]. - Product candidates SC291 in oncology, SC379, and SG299 were less promising than represented [1]. - To preserve cash, Sana was likely to decrease funding for or discontinue certain product candidates and significantly reduce its workforce [1]. - Defendants overstated Sana's financial capacity to maintain operations and advance existing product candidates [1]. Class Action Details - Shareholders who purchased shares of SANA during the class period are encouraged to register for the class action, with a deadline of May 20, 2025, to seek lead plaintiff status [2]. - Registration allows shareholders to receive updates throughout the lifecycle of the case, with no cost or obligation to participate [2]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].